Quotient BioResearch launches with acquisition of HFL

Quotient BioResearch announced its launch today with the acquisition of HFL, a UK-based firm that provides research and development support to pharmaceutical and biotech companies. "HFL is the first acquisition for Quotient BioResearch and an excellent fit for our strategy of building a major presence in early stage drug development and related services," said Paul Cowan. The company is planning other acquisitions of companies involved in early-stage research work.

- here's the release on the new company

Suggested Articles

The FDA’s advisory committee chair has stepped down from reviewing the upcoming pandemic vaccines given her role in Moderna’s COVID-19 test.

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.